title: Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic β-cell function in subjects with type 2 diabetes mellitus.
abstract: We searched for factors influencing the clinical effects of GLP-1 analogue liraglutide in subjects with type 2 diabetes. Multivariate analyses showed that hypertriglyceridemia and baseline HbA1c levels were independent predictors for the efficacy of liraglutide and that CPR index was an independent predictor for the durability of liraglutide.
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School.
authors.forename: Akihito
authors.initials: A
authors.lastname: Tanabe
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kaneto
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School. Electronic address: s.kamei@med.kawasaki-m.ac.jp.
authors.forename: Shinji
authors.initials: S
authors.lastname: Kamei
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School.
authors.forename: Hidenori
authors.initials: H
authors.lastname: Hirukawa
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School.
authors.forename: Masashi
authors.initials: M
authors.lastname: Shimoda
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Kimura
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Obata
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School.
authors.forename: Seizo
authors.initials: S
authors.lastname: Okauchi
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School.
authors.forename: Fuminori
authors.initials: F
authors.lastname: Tatsumi
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School.
authors.forename: Kenji
authors.initials: K
authors.lastname: Kohara
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School.
authors.forename: Tomoatsu
authors.initials: T
authors.lastname: Mune
authors.affiliation: Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School.
authors.forename: Kohei
authors.initials: K
authors.lastname: Kaku
mesh_terms: D001786:Blood Glucose; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives; D006801:Humans; D015228:Hypertriglyceridemia / Q000150:complications*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D050417:Insulin-Secreting Cells / Q000473:pathology*; D000069450:Liraglutide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1
keywords: Liraglutide; Llipid control; Pancreatic β-cell function